Lessons from the PROVE-IT trial. Higher dose of potent statin better for high-risk patients

Article Type
Changed
Mon, 10/08/2018 - 10:14
Display Headline
Lessons from the PROVE-IT trial. Higher dose of potent statin better for high-risk patients
Article PDF
Author and Disclosure Information

Kiran K. Khush, MD
Division of Cardiology, Department of Medicine, University of California, San Francisco

David Waters, MD
Division of Cardiology, Department of Medicine, University of California, San Francisco, and San Francisco General Hospital

Address: Kiran K. Khush, MD, Division of Cardiology, Department of Medicine, 505 Parnassus Avenue, Box 0124, San Francisco, CA 94143; e-mail kkhush@medicine.ucsf.edu

Dr. Waters has indicated that he is on the speakers’ bureau of Pfizer, Merck, and AstraZeneca, and has received grant or research support from AstraZeneca and Merck.

Issue
Cleveland Clinic Journal of Medicine - 71(8)
Publications
Topics
Page Number
609-616
Sections
Author and Disclosure Information

Kiran K. Khush, MD
Division of Cardiology, Department of Medicine, University of California, San Francisco

David Waters, MD
Division of Cardiology, Department of Medicine, University of California, San Francisco, and San Francisco General Hospital

Address: Kiran K. Khush, MD, Division of Cardiology, Department of Medicine, 505 Parnassus Avenue, Box 0124, San Francisco, CA 94143; e-mail kkhush@medicine.ucsf.edu

Dr. Waters has indicated that he is on the speakers’ bureau of Pfizer, Merck, and AstraZeneca, and has received grant or research support from AstraZeneca and Merck.

Author and Disclosure Information

Kiran K. Khush, MD
Division of Cardiology, Department of Medicine, University of California, San Francisco

David Waters, MD
Division of Cardiology, Department of Medicine, University of California, San Francisco, and San Francisco General Hospital

Address: Kiran K. Khush, MD, Division of Cardiology, Department of Medicine, 505 Parnassus Avenue, Box 0124, San Francisco, CA 94143; e-mail kkhush@medicine.ucsf.edu

Dr. Waters has indicated that he is on the speakers’ bureau of Pfizer, Merck, and AstraZeneca, and has received grant or research support from AstraZeneca and Merck.

Article PDF
Article PDF
Issue
Cleveland Clinic Journal of Medicine - 71(8)
Issue
Cleveland Clinic Journal of Medicine - 71(8)
Page Number
609-616
Page Number
609-616
Publications
Publications
Topics
Article Type
Display Headline
Lessons from the PROVE-IT trial. Higher dose of potent statin better for high-risk patients
Display Headline
Lessons from the PROVE-IT trial. Higher dose of potent statin better for high-risk patients
Sections
Disallow All Ads
Alternative CME
Use ProPublica
Article PDF Media